Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2016 | Pages:
212 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H2 2016', provides an overview of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - The report reviews pipeline therapeutics for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) therapeutics and enlists all their major and minor projects - The report assesses Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Overview 9 Therapeutics Development 10 Pipeline Products for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Overview 10 Pipeline Products for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Comparative Analysis 11 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics under Development by Companies 12 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics under Investigation by Universities/Institutes 15 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Unknown Stage Products 19 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Products under Development by Companies 20 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Products under Investigation by Universities/Institutes 24 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Companies Involved in Therapeutics Development 25 Aeolus Pharmaceuticals, Inc. 25 Angion Biomedica Corp. 26 Atox Bio Ltd. 27 BCN Biosciences L.L.C. 28 Bolder Biotechnology, Inc. 29 Cellerant Therapeutics, Inc. 30 Cellphire, Inc. 31 Chrysalis BioTherapeutics, Inc. 32 Cleveland BioLabs, Inc. 33 Cumberland Pharmaceuticals, Inc. 34 Diffusion Pharmaceuticals Inc. 35 GNI Group Ltd. 36 Humanetics Corporation 37 INSYS Therapeutics, Inc. 38 Meabco A/S 39 Neumedicines Inc. 40 Nohla Therapeutics Inc. 41 Onconova Therapeutics, Inc. 42 Original BioMedicals Co. Ltd. 43 PharmaIN Corporation 44 Pluristem Therapeutics Inc. 45 RDD Pharma Ltd. 46 Reata Pharmaceuticals, Inc. 47 RedHill Biopharma Ltd. 48 RxBio, Inc. 49 SK Chemicals Co., Ltd. 50 Soligenix, Inc. 51 Stemedica Cell Technologies, Inc. 52 Terapio Corporation 53 Tonix Pharmaceuticals Holding Corp. 54 Vida Therapeutics Inc. 55 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics Assessment 56 Assessment by Monotherapy Products 56 Assessment by Target 57 Assessment by Mechanism of Action 60 Assessment by Route of Administration 63 Assessment by Molecule Type 65 Drug Profiles 67 A-02 - Drug Profile 67 AB-103 - Drug Profile 68 ABC-294640 - Drug Profile 71 AEOL-10150 - Drug Profile 76 AEOL-10171 - Drug Profile 85 amifostine - Drug Profile 86 Antisense RNAi Oligonucleotide for Influenza, Rheumatoid Arthritis and Radiation-Induced Fibrosis - Drug Profile 87 AVMOC-001 - Drug Profile 88 BB-3 - Drug Profile 89 BBT-007 - Drug Profile 92 BBT-015 - Drug Profile 93 BBT-018 - Drug Profile 94 BBT-059 - Drug Profile 95 BCN-057 - Drug Profile 96 BIO-300 - Drug Profile 97 BMX-001 - Drug Profile 100 BPC-2 - Drug Profile 101 C-2E2 - Drug Profile 102 C-2E5 - Drug Profile 103 Cell Therapy for Acute Radiation Syndrome - Drug Profile 104 cerium oxide - Drug Profile 105 CLT-009 - Drug Profile 106 Des-Asp Angiotensin 1 - Drug Profile 107 Drug to Antagonize Adenosine A2A Receptor for Radiation Dermatitis - Drug Profile 108 entolimod - Drug Profile 109 EWA-001 - Drug Profile 116 HSJ-0017 - Drug Profile 117 JP4-039 - Drug Profile 118 LGM-2605 - Drug Profile 120 m-2A2 - Drug Profile 121 molgramostim - Drug Profile 122 monosodium luminol - Drug Profile 123 NMIL-121 - Drug Profile 125 omaveloxolone - Drug Profile 128 ondansetron hydrochloride - Drug Profile 131 ondansetron hydrochloride CR - Drug Profile 132 Peptide to Agonize GHSR-1a for Acute Ischemic Stroke, Acute Radiation Syndrome, and Sepsis - Drug Profile 137 pirfenidone - Drug Profile 138 PLXR-18 - Drug Profile 140 RDD-2007 - Drug Profile 146 recilisib sodium - Drug Profile 147 Recombinant Protein C for Sepsis, Stroke and Radiation Toxicity - Drug Profile 149 Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury, and Sepsis - Drug Profile 150 Recombinant Protein to Activate FGF-4 for Radiation Injury - Drug Profile 151 Recombinant Protein to Activate FGF-7 for Radiation Injury - Drug Profile 152 RES-529 - Drug Profile 153 RP-239X - Drug Profile 157 rusalatide acetate - Drug Profile 158 Rx-100 - Drug Profile 161 SGX-201 - Drug Profile 163 SGX-202 - Drug Profile 164 SKI-2162 - Drug Profile 167 Small Molecule to Inhibit GSK-3 for Acute and Late Radiation Injury - Drug Profile 168 Small Molecules for Radiation and Chemical Toxicity - Drug Profile 169 Small Molecules for Radiation Toxicity - Drug Profile 170 Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Dermatology - Drug Profile 171 ST-266 - Drug Profile 172 ST-7 - Drug Profile 174 Stem Cell Therapy for Bacterial Sepsis, Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease and Toxicology - Drug Profile 175 SY-303A - Drug Profile 181 SY-513 - Drug Profile 182 SYGN-305 - Drug Profile 183 SYGN-399 - Drug Profile 184 Thrombosomes - Drug Profile 185 TPO-7630 - Drug Profile 186 TPO-7640 - Drug Profile 187 VEDA-1209 - Drug Profile 188 VTI-1000 Series - Drug Profile 189 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects 190 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Discontinued Products 195 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Product Development Milestones 196 Featured News & Press Releases 196 Appendix 206 Methodology 206 Coverage 206 Secondary Research 206 Primary Research 206 Expert Panel Validation 206 Contact Us 206 Disclaimer 207
List of Tables
Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H2 2016 15 Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Comparative Analysis, H2 2016 16 Number of Products under Development by Companies, H2 2016 17 Number of Products under Development by Companies, H2 2016 (Contd..1) 18 Number of Products under Development by Companies, H2 2016 (Contd..2) 19 Number of Products under Investigation by Universities/Institutes, H2 2016 20 Comparative Analysis by Late Stage Development, H2 2016 21 Comparative Analysis by Clinical Stage Development, H2 2016 22 Comparative Analysis by Early Stage Development, H2 2016 23 Comparative Analysis by Unknown Stage Development, H2 2016 24 Products under Development by Companies, H2 2016 25 Products under Development by Companies, H2 2016 (Contd..1) 26 Products under Development by Companies, H2 2016 (Contd..2) 27 Products under Development by Companies, H2 2016 (Contd..3) 28 Products under Investigation by Universities/Institutes, H2 2016 29 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Aeolus Pharmaceuticals, Inc., H2 2016 30 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Angion Biomedica Corp., H2 2016 31 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Atox Bio Ltd., H2 2016 32 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by BCN Biosciences L.L.C., H2 2016 33 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Bolder Biotechnology, Inc., H2 2016 34 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cellerant Therapeutics, Inc., H2 2016 35 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cellphire, Inc., H2 2016 36 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Chrysalis BioTherapeutics, Inc., H2 2016 37 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cleveland BioLabs, Inc., H2 2016 38 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cumberland Pharmaceuticals, Inc., H2 2016 39 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Diffusion Pharmaceuticals Inc., H2 2016 40 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by GNI Group Ltd., H2 2016 41 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Humanetics Corporation, H2 2016 42 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by INSYS Therapeutics, Inc., H2 2016 43 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Meabco A/S, H2 2016 44 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Neumedicines Inc., H2 2016 45 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Nohla Therapeutics Inc., H2 2016 46 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Onconova Therapeutics, Inc., H2 2016 47 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Original BioMedicals Co. Ltd., H2 2016 48 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by PharmaIN Corporation, H2 2016 49 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Pluristem Therapeutics Inc., H2 2016 50 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RDD Pharma Ltd., H2 2016 51 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Reata Pharmaceuticals, Inc., H2 2016 52 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RedHill Biopharma Ltd., H2 2016 53 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RxBio, Inc., H2 2016 54 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by SK Chemicals Co., Ltd., H2 2016 55 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Soligenix, Inc., H2 2016 56 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Stemedica Cell Technologies, Inc., H2 2016 57 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Terapio Corporation, H2 2016 58 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Tonix Pharmaceuticals Holding Corp., H2 2016 59 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Vida Therapeutics Inc., H2 2016 60 Assessment by Monotherapy Products, H2 2016 61 Number of Products by Stage and Target, H2 2016 63 Number of Products by Stage and Mechanism of Action, H2 2016 66 Number of Products by Stage and Route of Administration, H2 2016 69 Number of Products by Stage and Molecule Type, H2 2016 71 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects, H2 2016 195 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects (Contd..1), H2 2016 196 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects (Contd..2), H2 2016 197 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects (Contd..3), H2 2016 198 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects (Contd..4), H2 2016 199 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Discontinued Products, H2 2016 200
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
